glp-1 agonists diabetes How Receptor Evolved from to Weight Loss Treatments Targeting GLP-1, GIP & GCG
Description
61 In clinical trials of liraglutide for MASLD, the dose setting is still mainly based on the diabetes condition
Ben attributes this to several factors: Proven effectiveness in clinical trials and real-world use Social media and press coverage showcasing dramatic weight loss stories Advances in drug delivery, including long-acting formulations and oral options Expanding indications beyond diabetes to include obesity treatment Were in a situation where its the right molecule at the right time, Ben notes
353 i2231
18, 4 Sept
Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT
Competition Analysis: The GLP-1 Receptor Agonist market is characterized by a fragmented structure, with several players competing across various segments and regions
